Oliver Engert Buys 2,458 Shares of Enovis (NYSE:ENOV) Stock

Enovis Corporation (NYSE:ENOV) insider Oliver Engert acquired 2,458 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were purchased at an average cost of $20.32 per share, with a total value of $49,946.56. Following the completion of the purchase, the insider owned 56,098 shares of the company’s stock, valued at approximately $1,139,911.36. The trade was a 4.58% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Oliver Engert also recently made the following trade(s):

• On Thursday, September 3rd, Oliver Engert bought 5,140 shares of Enovis stock. The stock was acquired at an average cost of $19.46 per share, for a total transaction of $100,024.40.
• On Monday, June 15th, Oliver Engert purchased 1,000 shares of Enovis stock. The shares were acquired at an average price of $20.92 per share, for a total transaction of $20,920.00.
• On Thursday, June 11th, Oliver Engert acquired 1,200 shares of Enovis stock. The stock was acquired at an average price of $21.62 per share, for a total transaction of $25,944.00.
• On Wednesday, June 10th, Oliver Engert bought 1,000 shares of Enovis stock. The shares were acquired at an average cost of $23.00 per share, for a total transaction of $23,000.00.

Enovis Trading Down 4.2%

Shares of Enovis stock traded down $0.82 during midday trading on Friday, reaching $18.58. 1,886,327 shares of the company’s stock traded hands, compared to its average volume of 1,200,013. The stock has a 50 day moving average of $25.50 and a 200-day moving average of $24.20. Enovis Corporation has a 12 month low of $18.52 and a 12 month high of $34.28. The company has a market cap of $1.07 billion, a PE ratio of -0.96 and a beta of 1.31. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.00 and a current ratio of 1.98.

Enovis (NYSE:ENOV) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.05. The business had revenue of $582.78 million for the quarter, compared to analysts’ expectations of $581.84 million. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The firm’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.79 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, equities analysts expect that Enovis Corporation will post 3.15 EPS for the current fiscal year.

Institutional Trading of Enovis

Hedge funds and other institutional investors have recently modified their holdings of the business. California State Teachers Retirement System grew its position in shares of Enovis by 1.2% in the 2nd quarter. California State Teachers Retirement System now owns 51,713 shares of the company’s stock worth $1,622,000 after buying an additional 621 shares during the period. MGO One Seven LLC boosted its stake in Enovis by 9.4% during the fourth quarter. MGO One Seven LLC now owns 7,581 shares of the company’s stock worth $202,000 after acquiring an additional 650 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after acquiring an additional 707 shares in the last quarter. Empowered Funds LLC grew its stake in shares of Enovis by 13.0% in the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock worth $249,000 after buying an additional 749 shares during the last quarter. Finally, Arax Advisory Partners purchased a new stake in shares of Enovis in the fourth quarter worth $29,000. 98.45% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. Citigroup reiterated a “market outperform” rating on shares of Enovis in a research report on Wednesday. Canaccord Genuity Group lowered their price objective on shares of Enovis from $50.00 to $45.00 and set a “buy” rating for the company in a report on Monday, August 17th. Evercore set a $32.00 price objective on Enovis in a research report on Monday, July 6th. Zacks Research upgraded Enovis from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 29th. Finally, BMO Capital Markets set a $27.00 target price on Enovis in a research report on Tuesday. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Enovis currently has an average rating of “Moderate Buy” and an average price target of $40.38.

Key Headlines Impacting Enovis

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: CEO Damien McDonald bought 13,035 shares for approximately $249,620, increasing his stake by 5.57%. A substantial open-market purchase by the chief executive may signal confidence that the recent selloff has pushed the stock below its perceived value. SEC filing on CEO purchase
• Positive Sentiment: Insider Oliver Engert purchased 5,140 shares worth approximately $100,024, raising his ownership by 9.16%. The additional insider buying provides another potential confidence signal for investors. SEC filing on insider purchase
• Positive Sentiment: Zacks upgraded Enovis to Rank #2, or “Buy,” citing improving earnings prospects. Analysts’ upward earnings revisions and technically oversold conditions also suggest the possibility of a near-term trend reversal. Zacks Buy rating article
• Positive Sentiment: Canaccord Genuity maintained a Buy rating on ENOV, reinforcing the view that the selloff may have created an attractive entry point. Canaccord Genuity rating article
• Neutral Sentiment: A Q2 comparison with other specialty medical-device companies provides industry context, but the item does not identify a new material change to Enovis’ outlook. Q2 earnings comparison
• Negative Sentiment: Wells Fargo lowered its ENOV price target to $33, while Citizens JMP reduced its target to $47. Although both targets remain above the current trading range, the cuts indicate more cautious valuation assumptions and may weigh on sentiment. Wells Fargo price-target article Citizens JMP price-target article

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.